Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2022-03-08 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Allergy Therapeutics at Cowen Health Conference
Regulatory Filings Classification · 99% confidence The document is identified by the RNS Number header and contains information about a company executive presenting at a specific industry conference (Cowen 42nd Annual Health Care Conference). It is a brief announcement detailing participation in an event, not a full financial report (like 10-K or IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding Notification. The text explicitly states it is distributed via 'Reach, the non-regulatory press release distribution service of RNS'. Since it is an announcement about company activity/investor relations that doesn't fit the specific categories like ER, IP, or AGM-R, and it is clearly a press release format, the most appropriate classification is the general regulatory/news announcement fallback, RNS, as it is a standard RNS distribution format, even if marked as 'non-regulatory' by Reach.
2022-03-08 English
Allergy Therapeutics at Investor Meet Company
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4615 characters) distributed via RNS, identified by the RNS Number and the 'Allergy Therapeutics PLC' header. The core content announces that management will be presenting on the Group's 'recently announced Interim Results for the six months ended 31 December 2021' on an external platform (Investor Meet Company). Since this is an announcement about an upcoming presentation related to financial results, and not the full results document itself (which would likely be an IR or ER), it fits best as a general regulatory announcement or a notice about an investor event. Given the options, it is a general announcement distributed through the regulatory news service (RNS). It is not a specific report type like 10-K, IR, or ER, but rather a notice about an upcoming investor presentation concerning those results. The document explicitly states it is distributed by 'Reach, the non-regulatory press release distribution service of RNS,' which suggests it is a general announcement rather than a mandatory regulatory filing like a 10-K or a formal Earnings Release (ER). Therefore, the most appropriate classification is Regulatory Filings (RNS) as a general announcement.
2022-03-07 English
Allergy Therapeutics plc – Interim Results
Earnings Release Classification · 100% confidence The document explicitly states it announces 'Interim Results for the six months ended 31 December 2021' and is dated '03 March 2022'. This content, detailing financial performance over a six-month period (H1 2022), is characteristic of an Interim or Quarterly Report (IR). Although it is released via RNS (indicated by 'RNS Number : 5111D'), the document itself contains the comprehensive financial highlights and operational review, making 'IR' the most accurate classification over a simple 'RPA' or 'RNS'. The length (over 40,000 characters) confirms it is the report content, not just an announcement of the report. H1 2022
2022-03-03 English
Allergy Therapeutics shares positive new data
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number (1155D) and is dated March 1, 2022. The content details the presentation of positive new data from clinical trials (Grass MATA MPL and VLP001) at the American Academy of Allergy Asthma and Immunology Annual Meeting. It includes quotes from the CEO and contact information typical of a press release distributed via the RNS system. Crucially, the footer explicitly states: "This information is provided by Reach, the non-regulatory press release distribution service of RNS... Reach announcements are identified with an orange label and the word “Reach" in the source column..." This indicates it is a general announcement, not a specific regulatory filing like a 10-K, AR, or ER. Since it is a general, non-regulatory announcement distributed via the RNS platform, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous announcements not covered by more specific codes, especially those distributed via RNS/Reach.
2022-03-01 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1942 characters) and contains the header 'RNS Number : 7687C' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, immediate operational announcement related to trading status, not a comprehensive financial report or a standard regulatory filing like 10-K or IR. Since it is a general regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories (like DIV, DIRS, ER, etc.), the most appropriate classification is the general Regulatory Filings category (RNS).
2022-02-24 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1925 characters) and contains the header 'RNS Number : 7652C' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, short-form regulatory update related to trading mechanics, not a comprehensive financial report or a standard earnings announcement. Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, ER, 10-K, etc.), the most appropriate classification is the general regulatory filing category.
2022-02-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.